US DHHS guidelines updated (July 2016)

Simon Collins, HIV i-Base

The leading US DHHS treatment guidelines were updated in July 2016.

Main changes include:

Updated to include new drugs and formulations, all with TAF instead of TDF.
In general, TAF is recommended whenever TDF is recommended.
Small changes include references to universal use of resistance tests before starting ART. This is based on 10-17% of new diagnoses in the US including resistance to at least one drug. ART should not be delayed while waiting for the results of these tests.
Testing for integrase inhibitor resistance is not needed in most circumstances.
The guidelines note that a new commercial test (GenoSure) is available to test cell-associate HIV DNA (ie for people with undetectable viral load) but that there is insufficient data to recommend use. (See: http://www.monogrambio.com/hiv-tests/suppression-management/genosure-archive).

Reference:

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. July 2016.
https://www.aidsinfo.nih.gov/guidelines

Links to other websites are current at date of posting but not maintained.